Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.2K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K
Narcolepsy01:07

Narcolepsy

695
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
695
Amyloid Fibrils03:03

Amyloid Fibrils

12.5K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.5K
Disorders of Leukocytes01:27

Disorders of Leukocytes

2.3K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lafora disease gene therapy: EPM2A but not EPM2B overexpression results in Lafora body formation.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

Neurofilament Light Chain as a Biomarker of Disease Progression in Lafora Disease.

Neurology. Genetics·2025
Same author

The 9th annual Lafora science symposium: a rare epilepsy community makes progress towards clinical readiness.

Epilepsy & behavior : E&B·2025
Same author

Autosomal Recessive Cerebellar Ataxias: Translating Genes to Therapies.

Annals of neurology·2025
Same author

Lithium exacerbates Lafora body formation in the Epm2a<sup>-/-</sup> Lafora disease mouse model.

Neuroscience letters·2025
Same author

Targeting the trunk of multi-root common epilepsy with gene therapy.

Molecular therapy. Methods & clinical development·2025
Same journal

Exploring the efficacy and safety of perampanel in epilepsia partialis continua: A case series.

Epileptic disorders : international epilepsy journal with videotape·2026
Same journal

Clinical utility and genetic landscape of exome sequencing in a large pediatric epilepsy cohort: Insights from a Turkish tertiary care center.

Epileptic disorders : international epilepsy journal with videotape·2026
Same journal

From electroclinical phenotype to adult SCN1A diagnosis: Insights from the correspondence between Carlo Alberto Tassinari and Charlotte Dravet.

Epileptic disorders : international epilepsy journal with videotape·2026
Same journal

NMDAR-antibody encephalitis: Seizure semiology and EEG findings.

Epileptic disorders : international epilepsy journal with videotape·2026
Same journal

Asymmetric sleep spindles after thalamic stroke.

Epileptic disorders : international epilepsy journal with videotape·2026
Same journal

Complete seizure freedom following minimally invasive laser callosotomy in a patient with lissencephaly type 1: Challenging the traditional paradigm.

Epileptic disorders : international epilepsy journal with videotape·2026
See all related articles

Related Experiment Video

Updated: Mar 14, 2026

Concanavalin A-Based Sedimentation Assay to Measure Substrate Binding of Glucan Phosphatases
09:07

Concanavalin A-Based Sedimentation Assay to Measure Substrate Binding of Glucan Phosphatases

Published on: December 23, 2022

1.9K

Lafora disease.

Julie Turnbull1, Erica Tiberia1, Pasquale Striano2

  • 1Program in Genetics and Genome Biology and Division of Neurology, Department of Paediatrics, The Hospital for Sick Children and the University of Toronto, Canada.

Epileptic Disorders : International Epilepsy Journal with Videotape
|October 6, 2016
PubMed
Summary
This summary is machine-generated.

Lafora disease, a genetic epilepsy, involves abnormal glycogen accumulation. Understanding laforin and malin gene functions is key to developing future Lafora disease treatments targeting glycogen synthesis.

Keywords:
EPM2AEPM2BLaforaglycogen phosphataselaforinmalinprogressive myoclonus epilepsiesubiquitin

More Related Videos

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
09:32

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

Published on: December 18, 2016

13.0K
Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
08:01

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Published on: March 22, 2012

29.7K

Related Experiment Videos

Last Updated: Mar 14, 2026

Concanavalin A-Based Sedimentation Assay to Measure Substrate Binding of Glucan Phosphatases
09:07

Concanavalin A-Based Sedimentation Assay to Measure Substrate Binding of Glucan Phosphatases

Published on: December 23, 2022

1.9K
Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
09:32

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

Published on: December 18, 2016

13.0K
Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
08:01

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Published on: March 22, 2012

29.7K

Area of Science:

  • Neurogenetics
  • Molecular Biology
  • Biochemistry

Background:

  • Lafora disease (LD) is an inherited epilepsy caused by mutations in EPM2A (laforin) and EPM2B (malin) genes.
  • Pathology involves abnormal glycogen accumulation forming Lafora bodies (LB) in various tissues, including the brain and liver.

Purpose of the Study:

  • To review the current understanding of Lafora disease pathogenesis, clinical presentation, and therapeutic strategies.
  • To highlight the critical role of laforin and malin in glycogen structure regulation.

Main Methods:

  • Literature review of Lafora disease genetics, pathology, and animal models.
  • Analysis of current therapeutic approaches and future directions.

Main Results:

  • LD presents clinically with adolescent-onset seizures and progressive neurological decline, typically fatal within 10 years.
  • Laforin and malin are crucial for maintaining normal glycogen structure; their dysfunction leads to LB formation.
  • Existing antiepileptic drugs show limited efficacy in managing LD symptoms and progression.

Conclusions:

  • Lafora disease pathogenesis is intrinsically linked to aberrant glycogen metabolism.
  • Future therapeutic strategies for Lafora disease show promise in targeting brain glycogen synthesis.